Drug Trial Radar · NCT06718634
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Jan 2, 2025
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, dose-escalation and extended-enrollment, nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in relapsed or refractory lymphoid malignancies.
Conditions
- Relapsed or Refractory Lymphoid Malignancies
Interventions
BL-M08D1Drug
Administration by intravenous infusion for a cycle of 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
- Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.